Survodutide
Phase 3Peptide
Boehringer IngelheimSurvodutide is a peptide that works as a Glucagon/glp-1 Dual Agonist.[2] It is being investigated across 2 indications, with its most advanced program in Phase 3.[1]
Survodutide is one of 94 peptide programs targeting Obesity. It is currently in Phase 3.
2
Indications
7
Total Trials
3
Active Trials
93
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
190 competitors in Obesity
#DrugCompanyPhaseTrials
1Maridebart Cafraglutide
AmgenPhase 3
Retatrutide
Eli LillyPhase 3
NNC0487-0111
Novo NordiskPhase 3
Gemtesa
Sumitomo Pharma America, Inc.Phase 3
Zenagamtide
Novo NordiskPhase 3
Berobenatide
PfizerPhase 3
Ribupatide
KKailera
Phase 3
Elecoglipron
AstraZenecaPhase 3
PF-08653944
PfizerPhase 3
Survodutide
Boehringer IngelheimPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Obesity2 trials
Overweight2 trials
Non-Alcoholic Steatohepatitis1 trial
Type 2 Diabetes1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Survodutide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Glucagon/glp-1 Dual Agonist[2]
- Modality
- Peptide[2]
- Highest Phase
- Phase 3[1]
- Company